AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12924542 — intervention group
Group type: EXPERIMENTAL
Intervention: SQV 800 mg with itraconazole
Number of subjects: 17
Study 11039131 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg sodium cromoglycate (SCG) 20 min before exercise
Number of subjects: 30
Study 11039131 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg sodium cromoglycate (SCG) 20 min before exercise
Number of subjects: 30
Study 11039131 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg sodium cromoglycate (SCG) 120 min before exercise
Number of subjects: 30
Study 11039131 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg sodium cromoglycate (SCG) 120 min before exercise
Number of subjects: 30
Study 11039131 — intervention group
Group type: COMPARATOR
Intervention: No SCG premedication (test 1)
Number of subjects: 30
Study 11039131 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg SCG 20 min before exercise
Number of subjects: 30
Study 11039131 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg SCG 120 min before exercise
Number of subjects: 30
Study 11039131 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg SCG 20 min before exercise
Number of subjects: 30
Study 11039131 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg SCG 120 min before exercise
Number of subjects: 30
Study 9161067 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face household interviews
Number of subjects: 1222
Study 9161067 — intervention group
Group type: COMPARATOR
Intervention: Telephone interviews
Number of subjects: 1222
Study 8479193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) alone (n = 15)
Number of subjects: 87
Study 8479193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) in combination with external beam (n = 27)
Number of subjects: 87
Study 8479193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 87
Study 3296153 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 26
Study 3296153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 29751787 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a SC 44 μg 3×/week
Number of subjects: 0
Study 29751787 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a SC 22 μg 3×/week
Number of subjects: 0
Study 29751787 — intervention group
Group type: COMPARATOR
Intervention: Placebo/delayed treatment (DTx)
Number of subjects: 0
Study 26893248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 30
Study 26893248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis using interferential current
Number of subjects: 30
Study 26893248 — intervention group
Group type: COMPARATOR
Intervention: Interferential current
Number of subjects: 30
Study 22735030 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling focusing on dietary fat, fibre and saccharose intake at four routine maternity clinic visits
Number of subjects: 399
Study 22736022 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-segment fixation
Number of subjects: 106
Study 22736022 — intervention group
Group type: COMPARATOR
Intervention: Short-segment fixation
Number of subjects: 106
Study 20448462 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus radiotherapy
Number of subjects: 106
Study 20448462 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus radiotherapy
Number of subjects: 106
Study 18702958 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (50 mg)
Number of subjects: 24
Study 18702958 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg)
Number of subjects: 24
Study 18702958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20552096 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring-loaded bite blocks
Number of subjects: 3
Study 20552096 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic bite blocks
Number of subjects: 3
Study 20552096 — intervention group
Group type: EXPERIMENTAL
Intervention: Both appliances
Number of subjects: 3
Study 20552096 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 16607791 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 0.5%
Number of subjects: 75
Study 16607791 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 0.1%
Number of subjects: 75
Study 16607791 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 0.1%
Number of subjects: 75
Study 12069449 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance ≤ 40 ml x min(‐1)
Number of subjects: 6252
Study 12069449 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance from 41 to 55 ml x min(‐1)
Number of subjects: 6252
Study 12069449 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance from 71 to 85 ml x min(‐1)
Number of subjects: 6252
Study 9713031 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Triggered Ventilation (PTV)
Number of subjects: 59
Study 9713031 — intervention group
Group type: COMPARATOR
Intervention: Conventional Mandatory Ventilation (CMV)
Number of subjects: 59
Study 9713031 — intervention group
Group type: COMPARATOR
Intervention: Control group (babies who died)
Number of subjects: 59
Study 7980596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cys311 variant allele in alcoholics
Number of subjects: 569
Study 7980596 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 569
Study 2925978 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine gum
Number of subjects: 0
Study 2925978 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 0
Study 29105516 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cycling program (n=33; 3 months, 3x30 minutes training/week)
Number of subjects: 59
Study 29105516 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=26)
Number of subjects: 59
Study 29105516 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cycling group (n=33)
Number of subjects: 59
Study 29105516 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching group (n=15)
Number of subjects: 59
Study 29105516 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-coaching group (n=16)
Number of subjects: 59
Study 29873212 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention combined with diazepam (2.5 mg once, twice a day)
Number of subjects: 108
Study 29873212 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment of sudden hearing loss (Control group)
Number of subjects: 108
Study 27063750 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental internal nasal dilator (IND)
Number of subjects: 54
Study 27063750 — intervention group
Group type: COMPARATOR
Intervention: Placebo internal nasal dilator (IND)
Number of subjects: 54
Study 23113597 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonance frequency analysis (RFA) measurements at 8 weeks post-implant placement
Number of subjects: 28
Study 23113597 — intervention group
Group type: COMPARATOR
Intervention: Resonance frequency analysis (RFA) measurements at implant placement
Number of subjects: 28
Study 22240263 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestimide 3 g/day
Number of subjects: 40
Study 22240263 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin alone
Number of subjects: 40
Study 21173510 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day discharge transradial percutaneous coronary intervention (TRI)
Number of subjects: 660
Study 21173510 — intervention group
Group type: COMPARATOR
Intervention: Outpatient department PCI with subsequent admission
Number of subjects: 660
Study 21173510 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 660
Study 17554695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (IPTi) after first dose
Number of subjects: 1070
Study 17554695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (IPTi) after second dose
Number of subjects: 1070
Study 17554695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (IPTi) after third dose
Number of subjects: 1070
Study 17554695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (IPTi) for first anemia episode
Number of subjects: 1070
Study 17554695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (IPTi) after last dose
Number of subjects: 1070
Study 15803071 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and spinal stabilization exercises (30 minutes, 8 treatments over 8 weeks)
Number of subjects: 80
Study 15803071 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 station exercise class (aerobic exercises, spinal stabilization exercises, and manual therapy, 8 treatments over 8 weeks)
Number of subjects: 80
Study 12480510 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment with standard needles at acupoint LI11 for 30 min
Number of subjects: 14
Study 12480510 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with placebo needles at acupoint LI11 for 30 min
Number of subjects: 14
Study 10088835 — intervention group
Group type: EXPERIMENTAL
Intervention: Water seal group
Number of subjects: 205
Study 10088835 — intervention group
Group type: COMPARATOR
Intervention: No water seal group
Number of subjects: 205
Study 10088835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 205
Study 7738860 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagination of treadmill exercise in athletes
Number of subjects: 12
Study 7738860 — intervention group
Group type: COMPARATOR
Intervention: Control task (imaging letters)
Number of subjects: 12
Study 7738860 — intervention group
Group type: COMPARATOR
Intervention: Control task (treadmill sound only)
Number of subjects: 12
Study 2289222 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐cyclodextrin‐piroxicam (20 mg daily for eight weeks)
Number of subjects: 30
Study 2289222 — intervention group
Group type: EXPERIMENTAL
Intervention: tenoxicam (dosage not specified, for eight weeks)
Number of subjects: 30
Study 7002483 — intervention group
Group type: EXPERIMENTAL
Intervention: Rociverine (10 or 20 mg given intravenously)
Number of subjects: 121
Study 7002483 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine butylbromide (20 or 40 mg given intravenously)
Number of subjects: 121
Study 31437287 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 67
Study 31437287 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital fall prevention protocols
Number of subjects: 67
Study 29217923 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led approach and health clubs linked with school events and parents
Number of subjects: 1000
Study 29217923 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 1000
Study 29217923 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led approach and health clubs
Number of subjects: 1000
Study 26476796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 0
Study 26476796 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study 23429925 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailor-made weight loss intervention
Number of subjects: 407
Study 23429925 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral glucosamine sulphate)
Number of subjects: 407
Study 23185985 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback intervention offered to participants
Number of subjects: 425
Study 23185985 — intervention group
Group type: COMPARATOR
Intervention: Control condition (intervention not offered)
Number of subjects: 425
Study 18613283 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care condition (harm-reduction based approach)
Number of subjects: 34
Study 18613283 — intervention group
Group type: COMPARATOR
Intervention: Enhanced referral condition
Number of subjects: 34
Study 18613283 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care condition
Number of subjects: 34
Study 17522506 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b 10 MIU/m (IFN-I group) thrice weekly for 16 weeks
Number of subjects: 80
Study 17522506 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 80
Study 17522506 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b 30 MIU/m (IFN-II group)
Number of subjects: 80
Study 17522506 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant interferon therapy
Number of subjects: 80
Study 15221054 — intervention group
Group type: COMPARATOR
Intervention: UDC + CDC (125 mg urso-/chenodeoxycholic acid per 25 kg body weight)
Number of subjects: 70
Study 15221054 — intervention group
Group type: EXPERIMENTAL
Intervention: M + UDC + CDC (62.5 mg UDC/CDC plus 125 mg menthol per 25 kg body weight)
Number of subjects: 70
Study 12063630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusafungine in spray 4 times daily
Number of subjects: 68
Study 12063630 — intervention group
Group type: COMPARATOR
Intervention: Control (standard postoperative therapy)
Number of subjects: 68
Study 12063630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusafungine in spray
Number of subjects: 68
Study 9640721 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 122
Study 9640721 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 122
Study 7855226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol, 30 mg orally
Number of subjects: 12
Study 7855226 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-HTP, 200 mg PO
Number of subjects: 12
Study 7855226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol alone
Number of subjects: 12
Study 7855226 — intervention group
Group type: COMPARATOR
Intervention: L-5-HTP
Number of subjects: 12
Study 2517747 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to a tale
Number of subjects: 100
Study 2517747 — intervention group
Group type: COMPARATOR
Intervention: Formal explanations at the classroom
Number of subjects: 100
Study 998549 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of pyridoxine supplementation
Number of subjects: 0
Study 998549 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of pyridoxine supplementation
Number of subjects: 0
Study 998549 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of pyridoxine supplementation
Number of subjects: 0
Study 998549 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of vitamin B6
Number of subjects: 0
Study 998549 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended Dietary Allowance for vitamin B6 during pregnancy
Number of subjects: 0
Study 30700262 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel intervention including SMS text messages, social support in walking groups, and community events
Number of subjects: 600
Study 30700262 — intervention group
Group type: COMPARATOR
Intervention: Control communities (n=600)
Number of subjects: 600
Study 28064469 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal, psychodynamically oriented psychotherapy for 8 weeks
Number of subjects: 40
Study 25720410 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired cerebrovascular reactivity (CVR) defined by breath-holding index (BHI <0.47; bottom quartile)
Number of subjects: 415
Study 25720410 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired CVR in patients with carotid large-vessel disease
Number of subjects: 415
Study 23676940 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT combined with standardized treatment for asthma
Number of subjects: 90
Study 23676940 — intervention group
Group type: COMPARATOR
Intervention: Standardized treatment alone
Number of subjects: 90
Study 21851904 — intervention group
Group type: EXPERIMENTAL
Intervention: BES (biolimus-eluting stents)
Number of subjects: 1707
Study 21851904 — intervention group
Group type: COMPARATOR
Intervention: SES (sirolimus-eluting stents)
Number of subjects: 1707
Study 21851904 — intervention group
Group type: EXPERIMENTAL
Intervention: BES
Number of subjects: 1707
Study 21851904 — intervention group
Group type: COMPARATOR
Intervention: SES
Number of subjects: 1707
Study 18372063 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption (1-7 drinks/week)
Number of subjects: 5477
Study 18372063 — intervention group
Group type: COMPARATOR
Intervention: Non-drinkers (abstainers)
Number of subjects: 5477
Study 17505249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile single-use catheters
Number of subjects: 13
Study 17505249 — intervention group
Group type: COMPARATOR
Intervention: Clean reused catheters
Number of subjects: 13
Study 17505249 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated catheters
Number of subjects: 13
Study 17505249 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated PVC catheters
Number of subjects: 13
Study 14747232 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based blood glucose monitoring system (IBGMS) for 12 weeks
Number of subjects: 110
Study 14747232 — intervention group
Group type: COMPARATOR
Intervention: Control group with usual outpatient management for 12 weeks
Number of subjects: 110
Study 14747232 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based blood glucose monitoring system (IBGMS) for patients with baseline HbA(1c) <7.0%
Number of subjects: 110
Study 14747232 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based blood glucose monitoring system (IBGMS) for patients with baseline HbA(1c) >= 7.0%
Number of subjects: 110
Study 11527798 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulaquine
Number of subjects: 0
Study 11527798 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine
Number of subjects: 0
Study 11527798 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 9578250 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled propofol administration
Number of subjects: 19
Study 9578250 — intervention group
Group type: COMPARATOR
Intervention: Operator-controlled propofol administration
Number of subjects: 19
Study 9578250 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (patient-controlled and operator-controlled)
Number of subjects: 19
Study 7715982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza A reassortant virus vaccine (10^5 or 10^6 TCID50) administered separately from routine immunizations
Number of subjects: 0
Study 7715982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza A reassortant virus vaccine (10^6 TCID50) administered with routine immunizations at 2 and 4 months of age
Number of subjects: 0
Study 7715982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza A reassortant virus vaccine (10^6 TCID50) administered with routine immunizations at 2 and 6 months of age
Number of subjects: 0
Study 2515717 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 10
Study 31464520 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified 14 driver genes associated with HCC
Number of subjects: 1074
Study 31464520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway crosstalk and protein interaction network analysis
Number of subjects: 1074
Study 31464520 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional analysis of 560 human genes
Number of subjects: 1074
Study 28454828 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (36 supervised sessions followed by home-based training)
Number of subjects: 2331
Study 28454828 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2331
Study 25591054 — intervention group
Group type: EXPERIMENTAL
Intervention: Verticalization with a tilt table at 65° and movement of the lower limbs with a robotic system for 30 minutes three times a week for 24 sessions
Number of subjects: 12
Study 25591054 — intervention group
Group type: COMPARATOR
Intervention: Robotic verticalization system with inactive lower‐limb movement system
Number of subjects: 12
Study 23443221 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea (3 mg·kg(‐1))
Number of subjects: 18
Study 21091330 — intervention group
Group type: EXPERIMENTAL
Intervention: AC-CPR mode
Number of subjects: 30
Study 21091330 — intervention group
Group type: COMPARATOR
Intervention: Standard defibrillator operation
Number of subjects: 30
Study 19566636 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular family visiting program
Number of subjects: 50
Study 19566636 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 16761891 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive behavioral intervention
Number of subjects: 0
Study 16761891 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 15531698 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg elemental Fe as (57)Fe-labeled sprinkles added to maize-based porridge
Number of subjects: 90
Study 15531698 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg elemental Fe as (57)Fe-labeled sprinkles added to maize-based porridge
Number of subjects: 90
Study 15531698 — intervention group
Group type: EXPERIMENTAL
Intervention: (58)Fe tracer (0.2 mg as ferrous citrate) infused intravenously
Number of subjects: 90
Study 15353051 — intervention group
Group type: EXPERIMENTAL
Intervention: Written prompt to elicit patient's concerns
Number of subjects: 110
Study 15353051 — intervention group
Group type: COMPARATOR
Intervention: Usual consultation
Number of subjects: 110
Study 11061523 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) infusion at 1, 2, or 4 mIU/min for 10 hours
Number of subjects: 19
Study 11061523 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (dex; 4 mg, iv) followed by OT infusion at 1 mIU/min
Number of subjects: 19
Study 11061523 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (dex; 4 mg, iv) followed by OT infusion at 2 or 4 mIU/min
Number of subjects: 19
Study 11061523 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (dex; 4 mg, iv) in obese subjects
Number of subjects: 19
Study 11061523 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) infusion at 1, 2, or 4 mIU/min in obese subjects
Number of subjects: 19